3 completed, 1 recruiting. .
Follow NanoAlvand: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Effectiveness Evaluation of Temozolomide (Amitzo, NanoAlvand) in Patients With Grade III and IV Glioma Tumors temozolomide - Brain Tumor, Grade III Glioma | Recruiting | NanoAlvand | 100 | 2026-03-22 | 2026-06-30 | |
| Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation Tofacitinib - Alopecia Totalis/Universalis, Alopecia Areata(AA) | Completed | NanoAlvand | 296 | 2020-08-04 | 2025-08-07 | |
| Alvocade® (Bortezomib) Safety and Effectiveness Study Bortezomib - Multiple Myeloma, Refractory | Completed | NanoAlvand | 57 | 2016-07-01 | 2023-08-25 | |
| Alvopem® (Pemetrexed) Safety Assessment Pemetrexed - Non Small Cell Lung Cancer, Malignant Pleural Mesothelioma | Completed | NanoAlvand | 199 | 2016-03-15 | 2024-10-23 |
Alopecia Areata (1) · Alopecia universalis (1) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Glioma (1) · Mesothelioma, Malignant (1) · Multiple Myeloma (1)
Bortezomib (1) · Pemetrexed (1) · Temozolomide (1) · tofacitinib (1)
Iran (2)
Adnan Khosravi, Assoc. Prof. (1) · Mani Ramzi, Prof. (1)